期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
case of familial hyperlipoproteinemia type Ⅲ hypertriglyceridemia induced acute pancreatitis: role for outpatient apheresis maintenance therapy 被引量:10
1
作者 Mohannad Abou saleh Emad Mansoor gregory s cooper 《World Journal of Gastroenterology》 SCIE CAS 2017年第40期7332-7336,共5页
Hypertriglyceridemic pancreatitis(HTGP) accounts for up to 10% of acute pancreatitis presentations in nonpregnant individuals and is the third most common cause of acute pancreatitis after alcohol and gallstones. Ther... Hypertriglyceridemic pancreatitis(HTGP) accounts for up to 10% of acute pancreatitis presentations in nonpregnant individuals and is the third most common cause of acute pancreatitis after alcohol and gallstones. There are a number of retrospective studies and case reports that have suggested a role for apheresis and insulin infusion in the acute inpatient setting. We report a case of HTGP in a male with hyperlipoproteinemia type Ⅲ who was treated successfully with insulin and apheresis on the initial inpatient presentation followed by bi-monthly outpatient maintenance apheresis sessions for the prevention of recurrent HTGP. We also reviewed the literature for the different inpatient and outpatient management modalities of HTGP. Given that there are no guidelines or randomized clinical trials that evaluate the outpatient management of HTGP, this case report may provide insight into a possible role for outpatient apheresis maintenance therapy. 展开更多
关键词 APHERESIS PANCREATITIS PLASMAPHERESIS OUTPATIENT HYPERTRIGLYCERIDEMIA
下载PDF
Colorectal cancer surveillance:What's new and what's next? 被引量:3
2
作者 Johnie Rose Knut Magne Augestad gregory s cooper 《World Journal of Gastroenterology》 SCIE CAS 2014年第8期1887-1897,共11页
The accumulated evidence from two decades of randomized controlled trials has not yet resolved the question of how best to monitor colorectal cancer(CRC)survivors for early detection of recurrent and metachronous dise... The accumulated evidence from two decades of randomized controlled trials has not yet resolved the question of how best to monitor colorectal cancer(CRC)survivors for early detection of recurrent and metachronous disease or even whether doing so has its intended effect.A new wave of trial data in the coming years and an evolving knowledge of relevant biomarkers may bring us closer to understanding what surveillance strategies are most effective for a given subset of patients.To best apply these insights,a number of important research questions need to be addressed,and new decision making tools must be developed.In this review,we summarize available randomized controlled trial evidence comparing alternative surveillance testing strategies,describe ongoing trials in the area,and compare professional society recommendations for surveillance.In addition,we discuss innovations relevant to CRC surveillance and outline a research agenda which will inform a more risk-stratified and personalized approach to follow-up. 展开更多
关键词 COLORECTAL cancer SURVEILLANCE FOLLOW-UP Recurrenc
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部